Oral Hypoglycaemics
Severe
Database
Additive hypoglycaemia
Reduce doses; monitor glucose
Source: Kimi deep-research + Cla
Drug reference
Insulin Aspart
Rapid-acting insulin analogue · Antidiabetic
Also known as Novolog, Fiasp, NovoRapid
START
SC immediately before meals (faster-aspart at meal start to +20 min); individualised by carb ratio
TYPICAL MAX
No fixed ceiling — titrate to prandial glucose
STOP IF
Hypoglycaemia (treat first)
WATCH
Pre/post-meal glucose, hypoglycaemia (renal impairment/missed meals), injection technique, correct product
CDSCO approvedSchedule HATC A10AB05
KDIGO 2024 + manufacturer label
- ONSET
- 15min · prandial onset
- PEAK
- 1.5h · peak
- t½
- 1h · effect t½
- DURATION
- 4h · prandial duration
EXCRETION
Enzymatic degradation (hepatic/renal)
route + CYP
INTERACTIONS
1 major
SEVERE in our sources
PREGNANCY
Acceptable in pregnancy when prandial insulin needed — commonly used; titrate to targets
FDA category + note
Top interactionssee all 5 →
- Oral HypoglycaemicsSevereDatabaseKimi deep-research + Cla
Available in India
7 branded formulations and 6 fixed-dose combinations. Look up specific brands in the Drugs workspace.
Mechanism
Recombinant insulin analogue (Asp-B28) with reduced hexamer self-association → faster SC absorption and rapid, short prandial insulin-receptor agonism mimicking physiological mealtime insulin (faster-acting formulation available).
Indications
Type 1 and type 2 diabetes mellitus — prandial (bolus) coverageInsulin pump (CSII); IV use in specialist/critical-care glycaemic control
Dosing
- Adult
- SC immediately before meal (faster-aspart: at meal start to 20 min after); individualised by carb counting/correction. CSII and IV in specialist settings.
- Pediatric
- Weight/meal-based, individualised (specialist).
- Renal adjustment
- Reduced insulin requirement — titrate down, monitor.
- Hepatic adjustment
- Variable requirement; titrate to glucose.
- Geriatric
- Conservative targets; hypoglycaemia risk.
- Max dose
- No fixed ceiling — titrated to prandial glucose
Pharmacokinetics
Onset
~10–20 min
Peak effect
~1–3 h
Duration
~3–5 h
Half-life
~1 h (SC effect)
Bioavailability
SC
Protein binding
Low
Metabolism
Hepatic/renal insulin-degrading enzyme
Excretion
Renal degradation
Contraindications
- Hypoglycaemia
- Hypersensitivity to insulin aspart/excipients
Side effects
Common
HypoglycaemiaWeight gainInjection-site lipohypertrophy/reactionsTransient visual changes on initiation
Serious
- Severe hypoglycaemia (coma/seizure)
- Severe hypokalaemia
- Severe hypersensitivity/anaphylaxis (rare)
Pregnancy & lactation
Pregnancy
Acceptable in pregnancy when prandial insulin needed — commonly used; titrate to targets
Lactation
Compatible — not orally bioavailable to infant; adjust maternal dose
Drug interactions
Alcohol
Moderate
Database
Unpredictable hypoglycaemia
Counsel; monitor glucose
Source: Kimi deep-research + Cla
Corticosteroids
Moderate
Database
Hyperglycaemia — increased prandial requirement
Up-titrate; monitor
Source: Kimi deep-research + Cla
Non Selective Beta Blockers
Moderate
Database
Mask hypoglycaemia symptoms; impaired recovery
Counsel; monitor glucose
Source: Kimi deep-research + Cla
Thiazide
Moderate
Database
Hyperglycaemia/hypokalaemia
Monitor glucose/potassium
Source: Kimi deep-research + Cla
Related guidelines
Gestational diabetes mellitus
FOGSI · Obstetrics & Gynaecology · 2023
Type 2 diabetes in adults
RSSDI · Endocrinology · 2022
Type 2 diabetes in adults
ICMR · Endocrinology · 2022
Fluid and electrolyte management in diabetes
RSSDI · Endocrinology · 2025
Diabetes management during Ramadan
ADA · Endocrinology · 2025
Other Rapid-acting insulin analogue drugs
Ask House about Insulin Aspart
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Katzung, BNF·Verified: 2026-05-19 · House clinical team·Cockpit curated: 2026-05-19